Health
Study assesses cardiovascular and renal outcomes for ertugliflozin in patients with type 2 diabetes – News-Medical.Net
A new study led by a cardiologist from Brigham and Women’s Hospital has assessed the cardiovascular and renal outcomes for ertugliflozin, an SGLT2 inhibitor prescribed for patients with type 2 diabetes to help them control blood sugar levels
Reviewed by Emily Henderson, B.Sc.Sep 25 2020
A new study led by a cardiologist from Brigham and Women’s Hospital has assessed the cardiovascular and renal outcomes for ertugliflozin, an SGLT2 inhibitor prescribed for patients with type 2 diabetes to help them control blood sugar levels.
The Evaluation of Ertugliflozin Efficacy and Safety Cardiovascular Outcomes Trial (VERTIS CV) found that the drug had a safety profile similar to that of other SGLT2 inhibitors and did not increase risk of maj…
-
Noosa News23 hours agoDeath of German shepherd Arnie prompts Brisbane community action to protect pets caught up in crime
-
General16 hours agoARIA Awards 2025 winners: Amyl & The Sniffers and Ninajirachi dominate
-
Noosa News17 hours agoPolice officer who tracked Toyah Cordingley’s phone gives evidence at Rajwinder Singh’s murder trial
-
Noosa News24 hours agoFrank Moneger identified as man accused of hit-and-run death of 17-year-old girl in Margate, Queensland